Radiolabeled Monoclonal Anti-Tumor Antibodies in Diagnosis and Therapy

摘要: Clinical work with radiolabeled anti-tumor antibodies has made remarkable progress in the past few years. Still, there is much to be done before these new reagents can have a substantial impact on practical management of patients. In this discussion, properties an “ideal” antibody and important factors for vivo localization tumors are reviewed. Potential approaches improving currently available “tumor specific” monoclonal discussed examples patients examined treated method presented. Experience date suggests that within foreseeable future, techniques will become “genuinely decisive technology.”